Quick Answer
Armata Pharmaceuticals, Inc. reported Cash and Equivalents of $8.69 million for fiscal year 2025.
Armata Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $8.69M | -6.5% |
| 2024 | $9.29M | -31.3% |
| 2023 | $13.52M | -8.9% |
| 2022 | $14.85M | +44.4% |
| 2021 | $10.29M | +6.6% |
| 2020 | $9.65M | +59.9% |
| 2019 | $6.03M | -37.6% |
| 2018 | $9.66M | +88.3% |
| 2017 | $5.13M | -10.1% |
| 2016 | $5.71M | -39.1% |
| 2015 | $9.37M | +42.4% |
| 2014 | $6.58M | -67.7% |
| 2013 | $20.36M | +2261.4% |
| 2012 | $862.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.76M | -13.9% | +240.9% |
| June 30, 2025 | $4.33M | -83.6% | -63.0% |
| March 31, 2025 | $11.69M | -69.1% | +25.8% |
| December 31, 2024 | $9.29M | -31.3% | -45.8% |
| September 30, 2024 | $17.14M | -28.5% | -35.1% |
| June 30, 2024 | $26.41M | +112.0% | -30.3% |
| March 31, 2024 | $37.86M | +50.8% | +180.0% |
| December 31, 2023 | $13.52M | -8.9% | -43.6% |
- Armata Pharmaceuticals, Inc. showed a decrease of -6.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, Armata Pharmaceuticals, Inc.’s cash and equivalents has grown by 907.9% (from $862.0 thousand to $8.69 million).
- The most recent figure is from Armata Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: